Winsbury-White Lecture
The Imunological Follow Up of Renal Aliograft Recipients by Professor Jean Hamburger mD (Hopital Necker, Paris 15e, France) Thirteen years have elapsed since the first renal allografts were successfully carried out in man. In those early days, in human as well as in experimental transplantations, the only tests for success or failure were clinical and pathological. Successful grafts were defined by a normal and stable function and satisfactory biopsy findings, while failure was revealed by renal insufficiency and severe lesions in the graft.
Clearly enough, however, when lesions appear in the graft they are only the end result of the host immunological response, and this should be evaluated before any damage has been done to the graft. The chief purpose of this lecture is to discuss whether it is possible to follow up these patients, not only on a clinical basis, but also with a regular evaluation of their immunological state.
My discussion will be limited to five main tests: the search for transformed lymphocytes in vivo, the mixed lymphocyte culture, the leukocyte migration inhibition test, the rosette test and the colony inhibition test. All these tests can be used to study the cell-mediated response and four of them can also detect circulating antibodies.
Detection ofTransformed Lymphocytes in vivo
It is now well established that a major phenomenon of the cell-mediated immune response against allografts is a remarkable transformation of lymphocytes, stimulated by donor cells, into large blast-like cells sometimes termed immunoblasts.
Even in clinically well tolerated renal grafts, a biopsy will often show some interstitial cell infiltration. When studied under the electron microscope some of these cells appear quite similar to immunoblasts (Galle & Montera 1962) . We have described a method of following this in vivo transformation of lymphocytes by collecting the renal graft lymph from dogs and men (Hamburger, Dimitriu, Bankir, Debray-Sachs & Auvert 1971) . This method is derived from the observations by Pedersen & Morris (1970) in sheep. Total renal lymph collection is easy in sheep, which have a single efferent lymph duct per kidney, but in dogs and men only one out of many lymph ducts can be catheterized. In spite of this drawback, it is possible to study the human graft lymph daily for up to ten days following renal transplantation. During the first days only pure, normal lymphocytes are found in the renal lymph. On the fourth or fifth day transformed lymphocytes may be seen in a number of cases (Fig 1) . These are identical to those found in vitro in mixed lymphocyte cultures. Their proportion in the lymph may rise to 20 % or more, and then slowly diminish. It is remarkable that the number of immunoblasts appearing in vivo in the lymph is more or less proportional to the degree of transformation of lymphocytes observed in mixed cultures performed between donor and recipient cells prior to transplantation (Table 1) .
In one case, where donor and recipient were of opposite sexes, chromosome studies proved that all the transformed lymphocytes collected from the graft belonged to the host and none to the donor. In some cases clinical manifestations of rejection followed the appearance of transformed cells in the transplant lymph.
Unfortunately, this method of following cell stimulation in renal graft recipients is rather difficult. It may be impossible for the surgeon to catheterize a lymph duct, or the lymph flow may stop prematurely due to coagulation. In any case, lymph cannot be collected for much longer than a week after transplantation. It is an experimental rather than a practical method of patient follow (-) and increase in tritiated thymidine incorporation (----) in lymph collectedfrom a cadaver kidney graft Hence it has been proposed that appearance of these same immunoblasts be sought in the circulating blood rather than in the lymph. At least two groups of investigators, Hersh et al. in the United States (1970) and Posen et al. (1971) in Canada, have suggested that an increase in the number of lymphoid blast cells in the blood may be detected during rejection crises by an increase in tritiated thymidine incorporation into blood mononuclear cells. In England, Parker & Mowbray (1971) also found an increase in uridine incorporation during rejection episodes. Using autoradiography, however, they quite unexpectedly noticed that incorporating cells were not transformed lymphocytes, but immature cells of the myeloid series. This was entirely confirmed in our laboratory ) and in that of Hdyry et al. in Finland (1972) . The reason for this appearance of immature granulocytic cells in the blood during rejection remained obscure until we found that it regularly followed the administration of high doses of corticosteroids commonly used to treat rejection, and also that this administration alone, in patients with no rejection, had a similar effect . It is well known that corticosteroids may induce an influx of immature cells from the bone marrow into the circulating blood. Hence the measurement of thymidine incorporation into blood leukocytes detects not the rejection itself but rather the effect of the treatment on the bone marrow. There may also be a few transformed lymphocytes in the blood of transplant recipients, but their number is too low for them to be found by measurement of thymidine incorporation or any other known clinical method.
Mixed Lymphocyte Culture (MLC)
The mixed culture of lymphocytes from donor and recipient induces the appearance of large blast cells similar to the above-mentioned immunoblasts. MLC is in some respects a simplified model of the sequence of graft immunity, starting with the recognition of the foreign antigens and ending with the production of sensitized cells specifically cytotoxic against donor cells (Hayry & Defendi 1970) . Another reason to consider MLC as a kind of dress rehearsal of the events to occur in vivo is the comparison between the results of MLC performed before transplantation and the outcome of the graft. In cases with a weak stimulation of recipient cells in vitro, the outcome of the renal allograft is statistically much better than in cases showing a clear-cut stimulation (Hamburger, Crosnier, Descamps & Rowinska 1971) .
When performed after the transplantation, MLC between donor cells and recipient lymphocytes could theoretically give information on Table I The in vivo stimulation (transformed cells in graft lymph) compared with the in vitro stimulation (as found in the mixed lymphocyte culture between donor and recipient prior to transplantation) Cadaver donors practically always give in vitro stimulation in MLC (1972) have published a few cases in which the mixed lymphocyte reaction was specifically depressed after transplantation. They have suggested that this may indicate immunological tolerance. However, they did not interrupt the immunosuppressive treatment to perform the test. We have shown that azathioprine administration could change cell reactivity in mixed lymphocyte cultures even when the lymphocytes are washed three times before the test. Hence, we studied the mixed lymphocyte reaction after a forty-eight hours' interruption of treatment. With this precaution, specific depression of the recipient cell reactivity is exceptional; on the contrary, a number of cases showed equal or increased activity after the graft. In some patients there is a nonspecific depression of reactivity (Debray-Sachs et al. 1972 ).
Leukocyte Migration Inhibition Test
Pioneers of this test were John David (David et al. 1964) and Bloom & Bennett (1966) . They showed that in the presence of a given antigen the lymphocytes of an animal sensitized against this antigen secreted a factor, called migration inhibition factor or MIF, which inhibits the migration of peritoneal macrophages out of capillary tubes.
An important practical advance was the demonstration by S0borg & Bendixen in 1967 that a similar test can be performned in man using circulating blood leukocytes. The test is not quite as simple as it seems at first glance, but with enough practice there is no serious difficulty and the reproducibility is excellent. In cadaver kidney transplantation, Jean Dormont and his co-workers in my laboratory (Galanaud et al. 1972 ) used extracts of the donor spleen as an antigen: the extracts are prepared by sonication and ultracentrifugation, and they are checked for their content of histocompatibility antigens. Using such an extract as antigen, we regularly studied leukocyte migration inhibition in 73 recipients. The test was found to be positive during most rejection episodes when performed before the corticosteroid treatment; it was also positive in 3 cases of hyperacute irreversible rejection. The test often becomes positive before any detectable clinical manifestations, so that it may be a useful tool for an early diagnosis of the rejection crisis. It usually becomes negative as soon as the corticosteroid treatment is started. The test was positive in only 10% of patients with a good and stable clinical condition, while it was positive in 26 % of cases in patients with chronic rejection. These results have recently been confirmed by Falk et al. (1972) . Other antigens, such as kidney extracts (Smith et al. 1969) The results are not as regular as with histocompatibility antigens but they are sometimes positive, so that there is not yet complete evidence of a strict immunological specificity of the reaction in transplanted patients. Dimitriu et al. (1972) showed in my laboratory that migration inhibition is not always the result of the secretion of MIF in the presence of the antigen. It may also occur when the medium contains traces of humoral antibodies against the individual supplying the migrating cells. Using rat spleen cells, for example, this test is much more sensitive than any other known test to detect allogenic antibodies produced by another strain of rat (Fig 2) . This may be useful in the future for the detection of circulating antibodies in transplanted patients. Unfortunately, this test is much less sensitive with blood leukocytes than with the spleen and it will not prevail over the present cytotoxicity tests for human cases until we can render it as sensitive with blood as it is with spleen cells.
Rosette Test
Research on the rosette test has been conducted in my group mainly by Jean-Fran9ois Bach and his co-workers (Bach & Dardenne 1971 , Bach et aL 1970 . A rosette is formed by the adherence of red blood cells around a lymphocyte. It is well known, since the work of Biozzi and many others, that 1-2 % of lymphocytes of a mouse immunized against sheep red blood cells will form rosettes with these erythrocytes when mixed with them in vitro. It is not this type of immune rosette that I am considering here, but spontaneous rosettes formed by animals having received no preimmunization. The number of these spontaneous rosettes is much smaller than that of immune rosettes, but the interesting point is that spon-taneous rosettes form a possible in vitro model of antigen recognition (Bach 1971a) . Evidence for this was given by the following experiment:
Mouse lymphocytes were allowed to form spontaneous rosettes against sheep red blood cells. Rosette-forming lymphocytes were separated from the lymphocyte population by a Ficoll-Triosil gradient. The population thus depleted was used to reconstitute mice whose lymphoid systems had been destroyed by cyclophosphamide. The mice reconstituted in this way could react against other antigens, such as chicken red blood cells, but could not react against sheep red blood cells. Conversely, a lymphocyte population depleted of cells forming rosettes against chicken red blood cells did restore antibody formation against sheep red blood cells but did not restore antibody formation against chicken red blood cells.
For our present purpose, one of the most interesting qualities of these spontaneous rosettes is their exquisite sensitivity to the immunosuppressive agents used in transplantation. Rosette formation is inhibited by a very low concentration of azathioprine or antilymphocyte serum (ALS). This fact has several practical implications.
The first concerns the evaluation and screening of immunosuppressive drugs (Bach 1971b ). In mice a series of 23 different preparations of ALS showed that the rosette inhibition titre and the capacity for prolonging skin allograft survival were parallel. About 50 human ALS prepared by various laboratories were then studied. Hans Balner tested them in Holland with his wellknown test of skin grafting in monkeys. J-F Bach tested the same preparations in Paris with the in vitro rosette studies. It turned out that the results of the in vitro and in vivo tests showed a close positive correlation. The rosette test is now used by many laboratories for ALS standardization and we and others express the ALS dosage given to patients in terms of rosette inhibition units instead of in millilitres.
Another use of the rosette inhibition test is more relevant to the subject of this Lecture, the follow up of the transplanted patient. Because of its remarkable sensitivity to azathioprine, the rosette inhibition test makes it possible to trace the activity reached at any time in the blood of animals or men receiving this drug. Heretofore the blood level of azathioprine could only be determined when using radioactive Imuran labelled with sulphur 35. The curve obtained with the rosette test after one dose of the drug closely follows the curve of sulphur 35, with a few differences. A 30 minutes' delay occurs between the peak of radioactive sulphur and the peak of rosette inhibition, suggesting that the most active material is not Imuran itself but Imuran metabolites formed during this time, and this has been proved in vitro. Imuran incubation with various cells, especially mouse red blood cells, increases the rosette inhibition titre of the solution by 40 to 1000 times. The activated Imuran probably includes thioinosinic acid.
Testing the rosette inhibition activity in the blood of animals or men receiving azathioprine is a very simple procedure which has led to several unexpected observations . Giving 150 mg of the drug daily in one single dose or in three separate doses of 50 mg each results in two quite different activity curves. Renal failure does not change the curve at all, despite a prolonged retention of 35S when using labelled Imuran (Fig 3) . Conversely, in liver insufficiency the 35S curve is normal, but the activity is greatly depressed or even nil (Fig 4) . This has been confirmed by Mitchell et al. (1970) and others. The lack of activity is not due to a lack of absorption since it is also found after intravenous injection. It suggests that the liver plays a major role in the transformation of the drug into its active metabolites. It is, of course, impossible to assert that the rosette inhibition activity and the immunosuppressive activity are identical. But this is highly probable since there is a close correlation between the effects of drugs Hence the measurement of the anti-rosette blood activity actually obtained in grafted patients receiving drugs could be a convenient tool to judge the degree of immunosuppression obtained by the treatment.
The results obtained in cases where normal doses of Imuran induced an early and profound bone marrow depression will also be considered. In 5 of these patients it was found that the titre of rosette inhibition in the plasma remained high for a prolonged period of time after a single dose of Imuran (Fig 5) . It was then easy to understand that normal dosage of the drug resulted in an abnormally high level of the active metabolites in the circulating blood. This abnormal disappearance curve is certainly caused by some genetic enzyme defect since similar curves were found in other members of the patients' families. Cases of gout existed in these families, a fact which is not surprising since Imuran is a purine derivative. In practice, the rosette test may be useful for the detection of patients subject to severe cytopenia despite a normal dosage of Imuran.
The most recent finding of the research group directed by J-F Bach and working on the rosette test in my laboratory is of purely theoretical interest for the moment, but is exciting and worthy of comment.
It must first be stressed that all rosette-forming lymphocytes are not equally sensitive to Imuran or ALS. To make a long story short, thymusdependent lymphocytes or T-lymphocytes are prevented from making rosettes by as little as 1 ,ug of azathioprine per ml, while B-lymphocytes found in bone marrow are only sensitive to 100-500 ,ug of azathioprine per ml ( Table 2 ). The remarkable sensitivity of T-lymphocytes to azathioprine is so specific that it can be used as a marker of these lymphocytes with results at least as safe as those of other known markers, using for example antigenic properties or surface immunofluorescent studies. The study of this new marker of T-lymphocytes, the rosette inhibition test, as well as of other markers has led to new and stimulating findings.' In the adult mouse thymectomy suppresses the rosette-forming cells' sensitivity to azathioprine within five days. This sensitivity is restored by acellular thymus extracts, or thymosin, kindly supplied to our laboratory by A L Goldstein working in New York and by N Trainin working in Israel. Thymosin may also induce the in vivo appearance of the same T-markers in a large proportion of bone marrow cells which are perhaps T-cell precursors (Bach et al. 1971) . And, last but not least, the serum of a normal mouse may also restore these T-markers in thymectomized mice, while they are not reconstituted by the serum of a thymectomized animal or of a nude mouse. These results suggest that a thymus hormone-like activity exists in normal serum and may be detected and measured with a simple test (Bach & Dardenne 1972) . Preliminary results in 4 men undergoing thymectomy are identical to those found in mice. In man as in the mouse it seems that this serum activity slowly 
Colony Inhibition Test
The fourth and last test was initially described in cancer immunology where it has been widely used by the Hellstroms and others. It consists in measuring the effect of lymphocytes or serum or both on culture of target cells, such as malignant cells in the case of cancer. In oncology I understand that the difficulties of this test are emphasized by most investigators. In transplantation, however, using donor fibroblasts as target cells, we found the method reasonably simple and safe ( Fig 6) . The Helistroms were the first to publish the use of this test in a few cases of human or experimental renal transplantation (Quadracci et al. 1971 ). Our experience with this test results from work conducted by Monique Sachs. It may be summarized as follows:
First, the recipient lymphocytes often acquire the power of inhibiting the growth of the donor's fibroblast colony; this may be a good method of detecting cell-mediated sensitivity in the allograft recipient. Secondly, circulating antibodies may also be detected in the serum by the same method. This is quite clear in rats but, in preliminary results with human transplantation, cytotoxic or 'enhancing' antibodies are far from constant. Finally, preliminary experiments in the rat suggest that passive enhancement may result in a delayed lymphocyte cytotoxicity. Skin from F1 August/ Lewis rats was grafted to Lewis rats, with or without administration of a dose of enhancing antibodies capable of prolonging graft survival by three days.
Six weeks later we found that the enhanced rats showed weaker lymphocyte cytotoxicity, but this was followed by a late rebound of this cell-mediated cytotoxicity at a time when control rats have no more detectable cytotoxicity (Debray-Sachs et al. 1973). The humoral response (circulating antibodies) is not affected. Lance & Batchelor (1968) , working with ALS' had already shown examples of the possible dissociation between the cell-mediated and humoral responses. Our findings, if confirmed, will underline a possible drawback of the use of enhancing sera in human transplantation. Here again the problem may be elucidated only by a more extensive study of in vitro tests detecting the actual immunological phenomena occurring in allograft recipients.
It is clear that a regular and satisfactory follow up of the immunological situation is still an aim rather than a present possibility in grafted patients. However, the few examples described will perhaps support my opinion that this line of research is fruitful and may bring forth a critical improvement in the techniques of organ transplantation during the coming years.
